Rafael Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
March 14, 2023 at 04:45 pm EDT
Share
Rafael Holdings, Inc. reported earnings results for the second quarter and six months ended January 31, 2023. For the second quarter, the company reported Revenue was USD 0.07 million compared to USD 0.074 million a year ago. Net loss was USD 3.25 million compared to USD 2.32 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.13 compared to USD 0.09 a year ago. Basic loss per share was USD 0.14 compared to USD 0.12 a year ago. Diluted loss per share was USD 0.14 compared to USD 0.12 a year ago.
For the six months, Revenue was USD 0.14 million compared to USD 0.265 million a year ago. Net loss was USD 1.66 million compared to USD 114.35 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 5.86 a year ago. Diluted loss per share from continuing operations was USD 0.36 compared to USD 5.86 a year ago. Basic loss per share was USD 0.08 compared to USD 5.91 a year ago. Diluted loss per share was USD 0.08 compared to USD 5.91 a year ago.
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Companyâs real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).